Recent Updates
Recently added Catalysts
PRCT Positive Sentiment Score: 75/100

PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June

Key Takeaway: PROCEPT BioRobotics will participate in four investor conferences in May and June 2025. These events include the Bank of America Health Care Conference and the Jefferies Global Healthcare Conference. The company aims to showcase its advancements in robotic solutions for urology, particularly in treating BPH. Webcasts of the presentations will be available for replay on their website.

Conference Participation Details

Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat

How to Access

Investors and the general public can listen to both sessions live at:

https://investor.viatris.com

Archived versions will be available following the live events for a limited time.

Market Sentiment Analysis

POSITIVE FACTORS

  • PROCEPT BioRobotics is actively engaging with investors through multiple conferences.
  • The company is focused on advancing patient care with innovative robotic solutions.
  • They have a strong clinical evidence base with over 150 peer-reviewed publications.

Full Press Release Details

SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at four upcoming investor conferences in May and June.

2025 Bank of America Health Care Conference

45thAnnual William Blair Growth Stock Conference

2025 Jefferies Global Healthcare Conference

2025 Truist Med-Tech Conference

A live webcast of each event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at:https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
About PROCEPT BioRobotics CorporationPROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM®and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:Matt BacsoVP, Investor Relations and Business Operationsm.bacso@procept-biorobotics.com

Frequently Asked Questions

Which conferences will PROCEPT BioRobotics attend?

PROCEPT BioRobotics will attend the Bank of America Health Care Conference, William Blair Growth Stock Conference, Jefferies Global Healthcare Conference, and Truist Med-Tech Conference.

What is the focus of PROCEPT BioRobotics?

The company focuses on advancing patient care through transformative robotic solutions in urology.

How can investors access the conference webcasts?

Investors can access the live webcasts and archived recordings on the 'Investors' section of the company's website.

What technology does PROCEPT BioRobotics use for BPH treatment?

They use the HYDROS Robotic System, which delivers Aquablation therapy, an AI-powered treatment for BPH.

Last updated: Apr 29, 2025